

*Agenda:* Committee Discussion.

*Place:* National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224.

*Closed:* October 24, 2006, 12:15 p.m. to 1:15 p.m.

*Agenda:* To review and evaluate personal qualifications and performance, and competence of individuals investigators.

*Place:* National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224.

*Open:* October 24, 2006, 1:15 p.m. to 3:45 p.m.

*Agenda:* Committee Discussion.

*Place:* National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224.

*Closed:* October 25, 2006, 3:45 p.m. to 4:45 p.m.

*Agenda:* To review and evaluate personal qualifications and performance, and competence of individuals investigators.

*Place:* National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224.

*Closed:* October 25, 2006, 8 a.m. to 8:30 a.m.

*Agenda:* To review and evaluate personal qualifications and performance, and competence of individuals investigators.

*Place:* National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224.

*Open:* October 25, 2006, 8:30 a.m. to 12:15 p.m.

*Agenda:* Committee Discussion.

*Place:* National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224.

*Closed:* October 25, 2006, 12:15 p.m. to 1:15 p.m.

*Agenda:* To review and evaluate personal qualifications and performance, and competence of individuals investigators.

*Place:* National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224.

*Open:* October 25, 2006, 1:15 p.m. to 2:30 p.m.

*Agenda:* Committee Discussion.

*Place:* National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224.

*Closed:* October 25, 2006, 2:30 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate personal qualifications and performance, and competence of individuals investigators.

*Place:* National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224.

*Contact Person:* Dan L. Longo, MD, Scientific Director, National Institute of Aging, Gerontology Research Center, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224-6825, 410-558-8110, [dl14q@nia.nih.gov](mailto:dl14q@nia.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: September 19, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06-8333 Filed 9-27-06; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Topics in Molecular Biology.

*Date:* October 10, 2006.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Rolf Menzel, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3196, MSC 7808, 3126 Bethesda, MD 20892, 301-435-0952, [menzelro@csr.nih.gov](mailto:menzelro@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Pancreas.

*Date:* October 13, 2006.

*Time:* 1 p.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Abubakar A. Shaikh, PhD, DVM, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6168, MSC 7892, Bethesda, MD 20892, (301) 435-1042, [shaikha@csr.nih.gov](mailto:shaikha@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Molecular Oncogenesis.

*Date:* October 16-17, 2006.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Washington Doubletree Hotel, 1515 Rhode Island Ave., NW., Washington, DC 20005.

*Contact Person:* Joanna M. Watson, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6046-G, MSC 7804, Bethesda, MD 20892, 301-435-1048, [watsonjo@csr.nih.gov](mailto:watsonjo@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Viral Vectors for Tumor Therapy.

*Date:* October 17, 2006.

*Time:* 2 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Eun Ah Cho, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6202, MSC 7804, Bethesda, MD 20892, (301) 451-4467, [choe@csr.nih.gov](mailto:choe@csr.nih.gov).

*Name of Committee:* Bioengineering Sciences & Technologies Integrated Review Group; Modeling and Analysis of Biological Systems Study Section.

*Date:* October 22-23, 2006.

*Time:* 6 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Malgorzata Klosek, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4188, MSC 7849, Bethesda, MD 20892, (301) 435-2211, [klosekm@mail.nih.gov](mailto:klosekm@mail.nih.gov).

*Name of Committee:* Endocrinology, Metabolism, Nutrition and Reproductive Sciences Integrated Review Group; Cellular, Molecular and Integrative Reproduction Study Section.

*Date:* October 23-24, 2006.

*Time:* 8 a.m. to 12 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Doubletree Hotel, 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Dennis Leszczynski, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6170, MSC 7892, Bethesda, MD 20892, (301) 435-1044, [leszczynski@csr.nih.gov](mailto:leszczynski@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Prion Biology and Neurodegeneration.

*Date:* October 23-24, 2006.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Toby Behar, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4136, MSC 7850, Bethesda, MD 20892, (301) 435-4433, [behart@csr.nih.gov](mailto:behart@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Biomedical Imaging and Bioinformatics.

*Date:* October 23–24, 2006.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Guo Feng Xu, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5122, MSC 7854, Bethesda, MD 20892, 301–435–1032, [xuguofen@csr.nih.gov](mailto:xuguofen@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Pilot and Feasibility Studies in Digestive Diseases and Nutrition (R21).

*Date:* October 23, 2006.

*Time:* 8 a.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Clarion Hotel Bethesda Park, 8400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Peter J. Perrin, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2180, MSC 7818, Bethesda, MD 20892, (301) 435–0682, [perrinp@csr.nih.gov](mailto:perrinp@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflicts: CIGP, GCMB, GMPB and HBPP.

*Date:* October 23–24, 2006.

*Time:* 8 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Patricia Greenwel, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2174, MSC 7818, Bethesda, MD 20892, (301) 435–1169, [greenwep@csr.nih.gov](mailto:greenwep@csr.nih.gov).

*Name of Committee:* Cardiovascular Sciences Integrated Review Group; Vascular Cell and Molecular Biology Study Section.

*Date:* October 23–24, 2006.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Doubletree Hotel and Executive Meeting Center, 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Anshumali Chaudhari, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4124, MSC 7802, Bethesda, MD 20892, (301) 435–1210, [chaudhaa@csr.nih.gov](mailto:chaudhaa@csr.nih.gov).

*Name of Committee:* Musculoskeletal, Oral and Skin Sciences Integrated Review Group; Arthritis, Connective Tissue and Skin Study Section.

*Date:* October 23–24, 2006.

*Time:* 8:30 a.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

*Contact Person:* Aftab A. Ansari, PhD, Scientific Review Administrator, Center for

Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892, (301) 594–6376, [ansaria@csr.nih.gov](mailto:ansaria@csr.nih.gov).

*Name of Committee:* Integrative, Functional and Cognitive Neuroscience Integrated Review Group; Central Visual Processing Study Section.

*Date:* October 24–25, 2006.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Doubletree Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Michael A. Steinmetz, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5172, MSC 7844, Bethesda, MD 20892, (301) 435–1247, [steinmem@csr.nih.gov](mailto:steinmem@csr.nih.gov).

*Name of Committee:* Infectious Diseases and Microbiology Integrated Review Group; Prokaryotic Cell and Molecular Biology Study Section.

*Date:* October 24–25, 2006.

*Time:* 8:30 a.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* St. Gregory Hotel, 2033 M Street, NW., Washington, DC 20036.

*Contact Person:* Diane L. Stassi, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3202, MSC 7808, Bethesda, MD 20892, (301) 435–2514, [stassid@csr.nih.gov](mailto:stassid@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; MEG Technology.

*Date:* October 24, 2006

*Time:* 2 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Lee Rosen, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5116, MSC 7854, Bethesda, MD 20892, (301) 435–1171, [rosenl@csr.nih.gov](mailto:rosenl@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Vision.

*Date:* October 24, 2006.

*Time:* 2 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Judith A. Finkelstein, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5178, MSC 7844, Bethesda, MD 20892, (301) 435–1249, [finkelsj@csr.nih.gov](mailto:finkelsj@csr.nih.gov).

*Name of Committee:* Health of the Population Integrated Review Group; Neurological, Aging and Musculoskeletal Epidemiology Study Section.

*Date:* October 25–26, 2006.

*Time:* 1 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Beacon Hotel and Corporate Quarters, 1615 Rhode Island Avenue, NW., Washington, DC 20036.

*Contact Person:* Heidi B. Friedman, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1012A, MSC 7770, Bethesda, MD 20892, (301) 435–1721, [hfriedman@csr.nih.gov](mailto:hfriedman@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; ZRG1 ONC–P (02): Boron Neutron Capture Therapy.

*Date:* October 25, 2006.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Zhiqiang Zou, MD, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6190, MSC 7804, Bethesda, MD 20892, (301) 451–0132, [zouzhiq@csr.nih.gov](mailto:zouzhiq@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Neurobiology of Sleep and Circadian Rhythms.

*Date:* October 25, 2006.

*Time:* 2 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Gamil C. Debbas, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5170, MSC 7844, Bethesda, MD 20892, (301) 435–1018, [debbasg@csr.nih.gov](mailto:debbasg@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Shared Instruments: Computers and Lithography.

*Date:* October 25, 2006.

*Time:* 3 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Sally Ann Amero, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4190, MSC 7849, Bethesda, MD 20892, (301) 435–1159, [ameros@csr.nih.gov](mailto:ameros@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Community-Based Participation in Research—R21s.

*Date:* October 25–26, 2006.

*Time:* 5 p.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Courtyard Marriott at Washingtonian Center, 204 Boardwalk Place, Gaithersburg, MD 20878.

*Contact Person:* Alfonso R. Latoni, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3139, MSC 7770, Bethesda, MD 20892, (301) 435–1735, [latonia@csr.nih.gov](mailto:latonia@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Assays and Detectors.

*Date:* October 25–26, 2006.

*Time:* 6 p.m. to 7 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Clarion Hotel Bethesda Park, 8400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Geoffrey White, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5148, MSC 7849, Bethesda, MD 20892, (301) 435–1735, [whitege@csr.nih.gov](mailto:whitege@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.983, National Institutes of Health, HHS)

Dated: September 19, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06–8331 Filed 9–27–06; 8:45 am]

BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Toxicology Program (NTP), NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); Notice of Availability of a Revised List of Recommended Reference Substances for Validation of *In Vitro* Estrogen and Androgen Receptor Binding and Transcriptional Activation Assays

**AGENCY:** National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH).

**ACTION:** Notice of the availability of a revised list of recommended reference substances.

**SUMMARY:** NICEATM announces the availability of an addendum to the report, “Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Evaluation of *In Vitro* Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays” [NIH Publication 03–4503]. The addendum describes the rationale for revisions to the original list of recommended reference substances for validation of *in vitro* estrogen receptor (ER) and androgen receptor (AR) binding and transcriptional activation (TA) assays.

#### SUPPLEMENTARY INFORMATION:

### Background

In April 2000, the Environmental Protection Agency (EPA) asked ICCVAM to evaluate the validation status of *in vitro* ER and AR binding and TA assays that were proposed as possible components of the EPA Endocrine Disruptor Screening Program Tier 1 screening battery. ICCVAM agreed to evaluate these test methods based on their potential interagency applicability and public health significance. NICEATM subsequently compiled available data and information on *in vitro* ER and AR binding and TA assays in four draft Background Review Documents (BRDs) (available at <http://iccvam.niehs.nih.gov/methods/endocrine.htm>).

In collaboration with the ICCVAM Endocrine Disruptor Working Group, NICEATM organized an independent scientific evaluation of the validation status of the four types of *in vitro* endocrine disruptor screening test methods on May 20–21, 2002, in Research Triangle Park, NC (**Federal Register**, Vol. 66, No. 57, pp. 16278–16279, March 23, 2001 and **Federal Register**, Vol. 66, No. 67, pp. 16415–16416, April 5, 2002, available at <http://iccvam.niehs.nih.gov/methods/endocrine.htm>).

The final BRDs and the ICCVAM Test Method Evaluation Report, which includes the expert panel report, public comments, and other relevant documents, were published in May 2003 and announced in the **Federal Register** notice (Vol. 68, No. 106, pp. 33171–33172, June 3, 2003, available at <http://iccvam.niehs.nih.gov/methods/endocrine.htm>).

NICEATM recently reviewed the commercial availability and cost for the 78 substances recommended by ICCVAM for use in *in vitro* ER and AR binding and TA validation studies. A minimum of 44 substances are recommended for AR binding and TA assays, while a minimum of 53 substances are recommended for ER binding and TA assays. This review indicated that three substances (anastrozole, CGS 18320B, and fadrozole) are not commercially available, one substance has restricted commercial availability (ICI 182,780) and six others (actinomycin D, hydroxyflutamide, 4-hydroxytamoxifen, methyltrienolone, 12-O-tetradecanoylphorbol-13-acetate, zearalenone) have costs that are considered excessive. ICCVAM has replaced the four substances, which are not commercially available or have restricted availability, with ones having similar ER and AR activity profiles (4-

hydroxyandrostenedione, chrysin, dicofol, raloxifene HCl). 19-nortestosterone and resveratrol were identified as replacements for two of the expensive substances, methyltrienolone and zearalenone respectively. NICEATM sought to replace four of the highly priced substances (actinomycin D, hydroxyflutamide, 4-hydroxytamoxifen, 12-O-tetradecanoylphorbol-13-acetate), but was unable to identify suitable replacements because of their unique activity profiles and/or chemical/physical properties. The proposed revisions were made available for public comment in March 2006 (**Federal Register**, Vol. 71, No. 51, pp. 13597–13598, March 16, 2006) and no comments were received. The final revised list of 78 reference substances recommended for validation of *in vitro* ER and AR binding and TA validation studies and a discussion about the revisions are now available in the document, “Addendum to the ICCVAM Evaluation of *In Vitro* Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays.” The addendum is available on the ICCVAM/NICEATM Web site at <http://iccvam.niehs.nih.gov> see “Test Method Evaluations” or by contacting NICEATM (requests should be sent by mail, fax, or e-mail to Dr. William S. Stokes, NICEATM Director, NIEHS, P. O. Box 12233, MD EC–17, Research Triangle Park, NC, 27709, (phone) 919–541–2384, (fax) 919–541–0947, (e-mail) [niceatm@niehs.nih.gov](mailto:niceatm@niehs.nih.gov)).

### Background Information on ICCVAM and NICEATM

ICCVAM is an interagency committee composed of representatives from 15 Federal regulatory and research agencies that use or generate toxicological information. ICCVAM conducts technical evaluations of new, revised, and alternative methods with regulatory applicability and promotes the scientific validation and regulatory acceptance of toxicological test methods that more accurately assess the safety and hazards of chemicals and products and that refine, reduce, or replace animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C. 285) establishes ICCVAM as a permanent interagency committee of the NIEHS under the NICEATM. NICEATM administers the ICCVAM and provides scientific and operational support for ICCVAM-related activities. NICEATM and ICCVAM work collaboratively to evaluate new and improved test methods applicable to the needs of Federal agencies. Additional information about ICCVAM and